Channels formed with a mutant prion protein PrP(82-146) homologous to a 7-kDa fragment in diseased brain of GSS patients

American Journal of Physiology - Cell Physiology

Volumn 285, Issue 4 54-4, 2003, Pages

  Bahadi, Randa ^a   Farrelly, Peter V ^a   Kenna, Bronwyn L ^a   Kourie, Joseph I ^a   Tagliavini, Fabrizio ^b   Forloni, Gianluigi ^c   Salmona, Mario ^c  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b Istituto Neurologico Carla Besta   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Amyloids; Cytotoxic proteins; Membrane linked pathologies; Neurodegenerative diseases; Prion channels; Prion diseases; Vacuolation

Indexed keywords

COPPER ION; ION CHANNEL; MUTANT PROTEIN; PRION PROTEIN; RIFAMPICIN;

AMINO ACID SEQUENCE; ARTICLE; GERSTMANN STRAUSSLER SCHEINKER SYNDROME; HUMAN; LIPID BILAYER; LIPID MEMBRANE; MEMBRANE CURRENT; NERVE CELL MEMBRANE; NEUROTOXICITY; PRIORITY JOURNAL; SEQUENCE HOMOLOGY;

EID: 0141679530     PISSN: 03636143     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpcell.00077.2003     Document Type: Article

References (62)

1. 2+ interaction with Alzheimer amyloid beta protein calcium channels. Proc Natl Acad Sci USA 93: 1710-1715, 1996.
2. Barry PH. JPCalc, a software package for calculating liquid junction potential corrections in patch-clamp, intracellular, epithelial and bilayer measurements and for correcting junction potential measurements. J Neurosci Methods 51: 107-116, 1994.
3. Baskakov IV, Aagaard C, Mehlhorn I, Wille H, Groth D, Baldwin MA, Prusiner SB, and Cohen FE. Self-assembly of recombinant prion protein of 106 residues. Biochemistry 39: 2792-2804, 2000.
4. Baskakov IV, Legname G, Baldwin MA, Prusiner SB, and Cohen FE. Pathway complexity of prion protein assembly into amyloid. J Biol Chem 277: 21140-21148, 2002.
5. Behl C, Davis JB, Lesley R, and Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77: 817-827, 1994.
6. Bhatia R, Lin H, and Lal R. Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. FASEB J 14: 1233-1243, 2003.
7. Bonetto V, Massignan T, Chiesa R, Morbin M, Mazzoleni G, Diomede L, Angeretti N, Colombo L, Forloni G, Tagliavini F, and Salmona M. Synthetic miniprion PrP106. J Biol Chem 277: 31327-31334, 2002.
8. Brown DR, Herms J, and Kretzsehmar HA. Mouse cortical cells lacking cellular PrP survive in culture with a neurotoxic PrP fragment. Neuroreport 5: 2057-2060, 1994.
9. Bush AI. Metal complexing agents as therapies for Alzheimer's disease. Neurobiol Aging 23: 1031-1038, 2002.
10. Chapron Y, Peyrin JM, Crouzy S, Jaegly A, and Dormont D. Theoretical analysis of the implication of PrP in neuronal death during transmissible subacute spongiform encephalopathies: hypothesis of a PrP oligomeric channel. J Theor Biol 204: 103-111, 2000.
11. Colquhoun D and Hawkes AG. Fitting and statistical analysis of single-channel recording. In: Single Channel Recording, edited by Sakmann B and Neher E. New York: Plenum, 1983, p. 135-175.
12. DeArmond SJ, Qiu Y, Wong K, Nixon R, Hyun W, Prusiner SB, and Mobley WE. Abnormal plasma membrane properties and functions in prion-infected cell lines. Cold Spring Harb Symp Quant Biol 61: 531-540, 1996.
13. Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O, and Tagliavini F. Neurotoxicity of a prion protein fragment. Nature 362: 543-546, 1993.
14. Gu Y, Fujioka H, Mishra RS, Li R, and Singh N. Prion peptide 106-126 modulates the aggregation of cellular prion protein and induces the synthesis of potentially neurotoxic transmembrane PrP. J Biol Chem 277: 2275-2286, 2002.
15. Harroun TA, Bradshaw JP, and Ashley RH. Inhibitors can arrest the membrane activity of human islet amyloid polypeptide independently of amyloid formation. FEBS Lett 507: 200-204, 2001.
16. Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, Torchia M, DeArmond SJ, Prusiner SB, and Lingappa VR. A transmembrane form of the prion protein in neurodegenerative disease. Science 279: 827-834, 1998.
17. Hirakura Y, Carreras I, Sipe JD, and Kagan BL. Channel formation by serum amyloid A: a potential mechanism for amyloid pathogenesis and host defense. Amyloid 9: 13-23, 2002.
18. Huang X, Cuajungco MP, Atwood CS, Hartshorn MA, Tyndall JD, Hanson GR, Stokes KC, Leopold M, Multhaup G, Goldstein LE, Scarpa RC, Saunders AJ, Lim J, Moir RD, Glabe C, Bowden EF, Masters CL, Fairlie DP, Tanzi RE, and Bush AI. Cu(II) potentiation of Alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 274: 37111-37116, 1999.
19. Jobling MF, Huang X, Stewart LR, Barnham KJ, Curtain CC, Volitakis I, Perugini M, White AR, Cherny RA, Masters CL, Barrow CJ, Collins SJ, Bush Al, and Cappai R. Copper and zinc binding modulates the aggregation and neurotoxic properties of the prion peptide PrP106-126. Biochemistry 40: 8073-8084, 2001.
20. Jobling MF, Stewart LR, White AR, McLean C, Friedhuber A, Maher F, Beyreuther K, Masters CL, Barrow CJ, Collins SJ, and Cappai R. The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of the prion peptide 106-126. J Neurochem 73: 1557-1565, 1999.
21. Kawahara M, Kuroda Y, Arispe N, and Rojas E. Alzheimer's disease - amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in hypothalamic GnRH neuronal cell line. J Biol Chem 275: 14077-14083, 2000.
22. Kourie JI. Vagaries of artificial bilayers and gating modes of the SCl channel from the sarcoplasmic reticulum muscle. J Membr Sci 116: 221-227, 1996.
23. Kourie JI. Mechanisms of prion-induced modification in membrane transport systems. Chem Biol Interact 138: 1-26, 2001.
24. Kourie JI. Prion channel proteins and their role in vacuolation and neuro degenerative diseases. Eur Biophys J 31: 409-416, 2002.
25. Kourie JI and Culverson AL. Prion peptide fragment PrP[106-126] forms distinct cation channel types. J Neurosci Res 62: 120-133, 2000.
26. Kourie JI, Culverson AL, Farrelly PV, Henry CL, and Laohachai KN. Heterogeneous amyloid-formed ion channels as a common cytotoxic mechanism: implications for therapeutic strategies against amyloidosis. Cell Biochem Biophys 36: 191-207, 2002.
27. Kourie JI, Farrelly PV, and Henry CL. Channel activity of deamidated isoforms of prion protein fragment 106-126 in planar lipid bilayers. J Neurosci Res 66: 214-220, 2001.
28. Kourie JI and Henry CL. Ion channel formation and membrane-linked pathologies of misfolded hydrophobic proteins: The role of dangerous unchaperoned molecules. Clin Exp Pharmacol Physiol 29: 741-753, 2002.
29. Kourie JI, Kenna BL, Tew D, Jobling MF, Curtain CC, Masters CL, Barnham KJ, and Cappai R. Copper modulation of ion channels of PrP[106-126] mutant prion peptide fragments. J Membr Biol 193: 35-45, 2003.
30. Kourie JI, Laver DR, Junankar PR, Gage PW, and Dulhunty AF. Characteristic of two types of chloride channel in sarcoplasmic reticulum vesicles from rabbit skeletal muscle. Biophys J 70: 202-221, 1996.
31. Lin H, Bhatia R, and Lal R. Amyloid β protein forms ion channels: Implications for Alzheimer's disease pathophysiology. FASEB J 15: 2433-2444, 2001.
32. 2+-sensitive channel in reconstituted lipid vesicles. Biochemistry 38: 11189-11196, 1999.
33. Lin MC and Kagan BL. Electrophysiologic properties of channels induced by A beta 25-35 in planar lipid bilayers. Peptides 23: 1215-1228, 2002.
34. Lin MC, Mirzabekov T, and Kagan BL. Channel formation by a neurotoxic prion protein fragment. J Biol Chem 272: 44-47, 1997.
35. Ma J, Wollmann R, and Lindquist S. Neurotoxicity and neurodegeneration when PrP accumulates in the cytosol. Science 298: 1781-1785, 2002.
36. ++-induced fusion of fragmented sarcoplasmic reticulum with artificial planar bilayers. J Membr Biol 30: 283-300, 1976.
37. Mirzabekov T, Lin MC, Yuan WL, Marshall PJ, Carman M, Tomaselli K, Lieberburg L, and Kagan BL. Channel formation in planar lipid bilayers by a neurotoxic fragment of the beta-amyloid peptide. Biochem Biophys Res Commun 202: 1142-1148, 1994.
38. Mobashery N, Nielsen C, and Andersen OS. The conformational preference of gramicidin channels is a function of lipid bilayer thickness. FEBS Lett 412: 15-20, 1997.
39. Muramoto T, Scott M, Cohen FE, and Prusiner SB. Recombinant scrapie-like prion protein of 106 amino acids is soluble. Proc Natl Acad Sci USA 93: 15457-15462, 1996.
40. Ono K, Hasegawa K, Yoshiike Y, Takashima A, Yamada M, and Naiki H. Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro. J Neurochem 81: 434-440, 2002.
41. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, and Greenamyre T. Early mitochondrial calcium defencts in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5: 731-736, 2002.
42. Patlak JB. Measuring kinetics of complex single ion channel data using mean-variance histograms. Biophys J 65: 29-42, 1993.
43. Post K, Pitschke M, Schafer O, Wille H, Appel TR, Kirsch D D, Mehlhorn I, Serban H, Prusiner SB, and Riesner D. Rapid acquisition of beta-sheet structure in the prion protein prior to multimer formation. Biol Chem 379: 1307-1317, 1998.
44. Qi JS and Qiao JT. Amyloid beta-protein fragment 31-35 forms ion channels in membrane patches excised from rat hippocampal neurons. Neuroscience 105: 845-852, 2001.
45. Salmona M, Forloni G, Diomede L, Algeri M, De Gioia L, Angeretti N, Giaccone G, Tagliavini F, and Bugiani O. A neurotoxic and gliotrophic fragment of the prion protein increases plasma membrane microviscosity. Neurobiol Dis 4: 47-57, 1997.
46. Sanderson KL, Butler L, and Ingram VM. Aggregates of a beta-amyloid peptide are required to induce calcium currents in neuron-like human teratocarcinoma cells: relation to Alzheimer's disease. Brain Res 744: 7-14, 1997.
47. Singh N, Gu Y, Bose S, Kalepu S, Mishra RS, and Verghese S. Prion peptide 106-126 as a model for prion replication and neurotoxicity. Front Biosci 7: 60-71, 2002.
48. Stewart LR, White AR, Jobling MF, Needham BE, Maher F, Thyer J, Beyreuther K, Masters CL, Collins SJ, and Cappai R. Involvement of the 5-lipoxygenase pathway in the neurotoxicity of the prion peptide PrP106-126. J Neurosci Res 65: 565-572, 2001.
49. Supattapone S, Bosque P, Muramoto T, Wille H, Aagaard C, Peretz D, Nguyen HO, Heinrich C, Torchia M, Safar J, Cohen FE, DeArmond SJ, Prusiner SB, and Scott M. Prion protein of 106 residues creates an artifical transmission barrier for prion replication in transgenic mice. Cell 96: 869-878, 1999.
50. Supattapone S, Bouzamondo E, Ball HL, Wille H, Nguyen HO, Cohen EF, DeArmond SJ, Prusiner SB, and Scott M. A protease-resistant 61-residue prion peptide causes neurodegeneration in transgenic mice. Mol Cell Biol 21: 2608-2616, 2001.
51. Tagliavini F, Forloni G, D'Ursi P, Bugiani O, and Salmona M. Studies on peptide fragments of prion proteins. Adv Protein Chem 57: 171-201, 2001.
52. Tagliavini F, Lievens PM, Tranchant C, Warter JM, Mohr M, Giaccone G, Perini F, Rossi G, Salmona M, Piccardo P, Ghetti B, Beavis RC, Bugiani O, Frangione B, and Prelli F. A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann-Straussler-Scheinker disease A117V. J Biol Chem 276: 6009-6015, 2001.
53. Tagliavini F, Prelli F, Porro M, Rossi G, Giaccone G, Farlow MR, Dlouhy SR, Ghetti B, Bugiani O, and Frangione B. Amyloid fibrils in Gerstmann-Straussler-Scheinker disease (Indiana and Swedish kindreds) express only PrP peptides encoded by the mutant allele. Cell 79: 695-703, 1994.
54. Tomiyama T, Asano S, Suwa Y, Morita T, Kataoka K, Mori H, and Endo N. Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro. Biochem Biophys Res Commun 204: 76-83, 1994.
55. Tomiyama T, Kaneko H, Kataoka K, Asano S, and Endo N. Rifampicin inhibits the toxicity of pre-aggregated amyloid peptides by binding to peptide fibrils and preventing amyloid-cell interaction. Biochem J 322: 859-865, 1997.
56. Tomiyama T, Shoji A, Kataoka K, Suwa Y, Asano S, Kaneko H, and Endo N. Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger. J Biol Chem 271: 6839-6844, 1996.
57. Tompa P, Tusnady GE, Cserzo M, and Simon I. Prion protein: evolution caught en route. Proc Natl Acad Sci USA 98: 4431-4436, 2001.
58. Volles MJ, Lee SJ, Rochet JC, Shtilerman MD, Ding TT, Kessler JC, and Lansbury PT Jr. Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40: 7812-7819, 2001.
59. Wang LM, Lashuel HA, Walz T, and Colon W. Murine apolipoprotein serum amyloid A in solution forms a hexamer containing a central channel. Proc Natl Acad Sci USA 99: 15947-15952, 2002.
60. Warwicker J. Modelling charge interactions in prion protein: predictions for pathogenesis. FEBS Lett 450: 144-148, 1999.
61. White AR, Guirguis R, Brazier MW, Jobling MF, Hill AF, Beyreuther K, Barrow CJ, Masters CL, Collins SJ, and Cappai R. Sublethal concentrations of prion peptide PrP106-126 or the amyloid beta peptide of Alzheimer's disease activates expression of proapoptotic markers in primary cortical neurons. Neurobiol Dis 8: 299-316, 2001.
62. Wille H, Michelitsch MD, Guenebaut V, Supattapone S, Serban A, Cohen FE, Agard DA, and Prusiner SB. Structural studies of the scrapie prion protein by electron crystallography. Proc Natl Acad Sci USA 99: 3563-3568, 2002.